The company has reported a net income of $258.14m, or $0.90 per diluted share, compared to net income of $117.48m or $0.39 per diluted share, for the same period last year.
Forest Labs chairman and CEO Howard Solomon said they initiated the scientific launches to health care professionals for their newest products, Daliresp and Viibryd and both products became available to patients in June.
"Daliresp and Viibryd will be formally launched to the medical community next month at the same national sales meeting of all of our salesforces," Solomon said.
"Upon the official launches of Daliresp and Viibryd, we will have launched a total of five products in just three years with three of those products launched in this current calendar year."